drugset / Trial / NCT00085891

Efficacy & Safety of Quetiapine Fumarate (SEROQUEL) & Placebo in the Treatment of Acutely Ill Patients With Schizophrenia

NCT00085891

Phase 3 Completed 535 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to demonstrate superior efficacy of sustained release quetiapine compared to placebo in patients with schizophrenia after receiving treatment for up to 6 weeks.

Timeline

Start
2004-06
Primary completion
Completion
2005-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule

Indications